Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FluorThanatrace PET/CT in Prostate Cancer
NCT03334500Phase 1Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2017
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FluorThanatrace in prostate cancer (PCa) (3 cohorts), sponsored by Abramson Cancer Center. Primary endpoint: Number of adverse events at 3 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03334500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334500.